Search

The article discusses a study that compares the effects of the psychedelic compounds 2C-B and psilocybin on brain organization using functional MRI in healthy volunteers. The research found that both compounds reduced intra-network connectivity while increasing between-network and subcortical-cortical connectivity. Additionally, 2C-B exhibited less pronounced reductions in between-network connectivity compared to psilocybin. The study suggests that 2C-B could be a valuable addition to psychedelic neuroscience research and may lead to new pharmacotherapy strategies. [Extracted from the article]

A recent pilot study conducted at the University of Oregon explored the effects of an intensive meditation practice known as Fire Kasina. The study found that participants reported experiences comparable to psychedelic and near-death experiences, with significant shifts in worldview. The research suggests that advanced meditation techniques may induce powerful transformative experiences similar to those induced by psychedelics. The study has been peer-reviewed and offers valuable insights into the potential benefits of mind-body therapies. [Extracted from the article]

A study published in Health & Medicine Week discusses the effects of a single high-dose of psilocybin on the human brain. The study found that psilocybin led to anatomical and functional brain changes in healthy, psychedelic-naive participants, with increases in cognitive flexibility, psychological insight, and well-being observed one month after use. The research also revealed correlations between decreased brain network modularity, improved well-being, and increased cortical signal entropy post-dosing. These effects were exclusive to the high-dose of psilocybin and not observed with a placebo. [Extracted from the article]

A survey conducted on federal grant submissions in the United States regarding therapeutic applications of psychedelics found that the number of grant applications increased notably after 2006. Of the 24 grant submissions for psychedelics assessed, 16.7% were funded, lower than the NIH's average funding rate for similar grants. Researchers believed that applications in this area had a lower chance of success compared to other research topics, but noted an improvement in funding landscape in recent years. The study has not yet undergone peer review. [Extracted from the article]

A patent application titled "Treatment Of Mental Health Diagnoses" by inventor Barbara Susan Schmitt discusses the safe and effective integration of patients during psychedelic-assisted treatments. The treatment involves administering psychedelic substances to induce altered states of consciousness, followed by an integration process to extract insights from the experience. The patent application outlines a method involving engaging patients with visual content to prompt self-reflection and positive storytelling post-treatment, aiming to improve therapeutic outcomes. [Extracted from the article]

A patent application titled "Liquid-Liquid Extraction Of Purified Psychoactive Alkaloid" was filed by inventors from Canada and made available online on October 3, 2024. The application focuses on the extraction of psychoactive compounds from psychedelic organisms, specifically Psilocybe cubensis mushrooms, using an acid extraction method to promote dephosphorylation. The process involves liquid-liquid extractions to yield a standardized and purified extract suitable for medical use, addressing challenges associated with natural extraction methods. The patent application aims to provide a more consistent and stable supply chain for psychoactive alkaloid compositions. [Extracted from the article]

The Department of Research has conducted new research on the potential use of psychedelic medicine, specifically psychedelic-assisted therapy (PAT), for treating eating disorders. The research suggests that psychedelic medicine may offer a valuable adjunct to existing treatments, addressing underlying psychological and transpersonal factors to enhance overall outcomes for individuals with eating disorders. The commentary aims to provide a multi-dimensional perspective on the application of psychedelic medicine in naturalistic, research, and clinical settings, offering new insights into healing approaches for eating disorders. [Extracted from the article]

A study protocol conducted by King's College London aims to investigate the effects of administering psilocybin, a psychedelic compound, to individuals with functional neurological disorder (FND). The research seeks to understand the potential mechanisms underlying FND by analyzing changes in brain networks, such as the default mode network (DMN), through functional magnetic resonance imaging (fMRI). The study will also assess the safety and feasibility of using psychedelics alongside psychological support in this patient population. Financial support for the research was provided by the Wellcome Trust. [Extracted from the article]

A study conducted by researchers at Amsterdam University Medical Center explored the correlation between the subjective effects of ketamine and psilocybin and their therapeutic outcomes in patients with depression or substance use disorder. The meta-analysis included 23 papers on ketamine and 8 papers on psilocybin, showing a modest role for subjective effects in mediating therapeutic outcomes, with a greater effect observed for psilocybin compared to ketamine, especially in treating depression. The research concluded that there is a greater mediating effect in substance use disorder compared to depression, regardless of treatment. [Extracted from the article]

A recent study conducted by researchers at Washington University School of Medicine has found that a single dose of psilocybin, a psychedelic substance, produces rapid and long-lasting therapeutic effects. The study tracked the brain changes of healthy adults before, during, and after high doses of psilocybin and methylphenidate, a stimulant medication. The results showed that psilocybin significantly disrupted functional connectivity in the brain, particularly in the default mode network, which is associated with our sense of space, time, and self. These findings suggest that the neuroplasticity induced by psilocybin may contribute to its therapeutic effects. [Extracted from the article]

A case study published in the Mental Health Weekly Digest explores the use of psilocybin and LSD as a self-treatment for depression and complex post-traumatic stress disorder (PTSD). The study focuses on a young man who experienced early-onset complex trauma and found traditional treatments ineffective. He turned to unsupervised self-treatment with psilocybin, gradually decreasing the dosage over time. The study suggests that psychedelic therapy may be a potential option for individuals with chronic treatment-resistant depression, but emphasizes the need for further research and caution. [Extracted from the article]

This article presents a case study of a woman in her early forties who experienced treatment-resistant depression due to early complex trauma. Traditional antidepressive medications did not alleviate her depression, so she turned to underground small-group therapy sessions that incorporated various techniques, including psilocybin mushrooms. After approximately 1.5 years and six psilocybin sessions, the woman achieved remission of her depression, which was confirmed in a follow-up interview 2.5 years later. This case study suggests that a multi-dose strategy over an extended period of time may be necessary to achieve remission in treatment-resistant depression with psychedelics. [Extracted from the article]

A retrospective study presented the case of a young woman who experienced abandonment-related anxiety. Traditional therapies did not benefit her, so she turned to psychedelics and found a therapist who used Internal Family Systems (IFS) methodology, MDMA, and LSD. Over the course of 1.5 years, she attended multiple therapy sessions and experienced a reliving of her birth trauma, which helped her understand and process her life history. She found the process beneficial and intended to continue it to stop the transmission of transgenerational trauma. This study has not been peer-reviewed. [Extracted from the article]

This article discusses the concept of the "mystical experience" in psychedelic therapy research. It highlights that while many studies mention this concept as a significant predictor of improved outcomes, they often do not provide detailed examples of such experiences. To address this, the article presents a case study of a man in his forties who attended psilocybin and MDMA sessions, which resulted in improved relationships with his parents, children, and wife. The article emphasizes the importance of understanding and adopting appropriate attitudes when facing these unexplainable or "mystical" phenomena in psychedelic therapy. Please note that this preprint has not been peer-reviewed. [Extracted from the article]

A recent study conducted by researchers at the University of Zurich explores the effects of combining the psychedelic substance N,N-dimethyltryptamine (DMT) with the monoamine oxidase inhibitor harmine (DMT-harmine) during meditation. The study involved 40 experienced meditators who participated in a three-day meditation retreat and received either a placebo or DMT-harmine. The results showed that meditators who received DMT-harmine reported greater levels of mystical-type experiences, non-dual awareness, emotional breakthroughs, and psychological insight compared to those who received the placebo. Additionally, participants who received DMT-harmine rated their experience as more personally meaningful, spiritually significant, and well-being-enhancing. The study highlights the specific effects of psychedelics during meditation and provides valuable insights into the potential benefits of mind-body therapy. [Extracted from the article]

A systematic review and meta-analysis conducted by researchers at Johns Hopkins University examined the adverse events (AEs) associated with classic psychedelics, such as LSD and psilocybin, in clinical or research settings. The study found that classic psychedelics were generally well tolerated, with serious AEs occurring in approximately 4% of participants with preexisting neuropsychiatric disorders. However, there were no reports of deaths by suicide, persistent psychotic disorders, or hallucinogen persisting perception disorders following administration of high-dose classic psychedelics. The researchers emphasized the need for ongoing pharmacovigilance to understand the risk and benefit profiles of these substances. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the potential of serotonergic psychedelics for treating neuropsychiatric disorders such as depression and addiction. The abstract presents a novel understanding of psychedelics based on systematic reviews and meta-analyses of three levels of analysis: subjective experience, neuroimaging, and molecular pharmacology. The results suggest that LSD yields higher ratings of visionary restructuralization compared to psilocybin, psychedelics strengthen between-network functional connectivity while diminishing within-network functional connectivity, and LSD induces more inositol phosphate formation at the 5-HT2A receptor than DMT and psilocin. The abstract emphasizes the need for standardizing experimental procedures and analysis techniques, as well as conducting more research on the emergence of different levels of psychedelic effects. [Extracted from the article]

A recent study conducted by researchers at Columbia University and published in Psychedelics has found that the psychedelic drug psilocybin, the active ingredient in "magic mushrooms," may have the potential to treat body dysmorphic disorder (BDD). BDD is a mental illness characterized by an obsessive preoccupation with perceived flaws in one's physical appearance. The study involved eight adults with moderate-to-severe BDD who had not responded to standard treatments. After receiving a single 25mg oral dose of psilocybin, the participants showed increased connectivity within brain networks involved in executive functions and processing emotionally salient stimuli. The researchers suggest that psilocybin may enhance cognitive and emotional functioning by facilitating communication within and between dysregulated brain networks. However, larger, placebo-controlled studies are needed to confirm the efficacy and durability of psilocybin therapy for BDD. [Extracted from the article]

A recent study compared the effects of the psychedelic drug psilocybin to the standard SSRI antidepressant escitalopram and found that both treatments led to similar improvements in depressive symptoms over a 6-month period. However, patients taking psilocybin also reported better psychosocial functioning, including a greater sense of meaning in life and psychological connectedness. The study suggests that psilocybin may offer additional benefits and could be an alternative for patients who do not respond to SSRIs. It is important to note that psilocybin is still an experimental drug and has not been approved for general use. [Extracted from the article]

A recent report from Imperial College London discusses the use of psychedelics in the treatment of addiction. The research highlights the historical use of psychedelic substances in ritualistic and ceremonial settings dating back to 8,500 BCE. The report reviews studies conducted over the past 40 years on classic psychedelics such as psilocybin and LSD, as well as atypical psychedelics like ketamine and ibogaine. The findings suggest that psychedelics show promise as therapeutic alternatives for addiction treatment, improving both psychological and physiological symptoms. The report emphasizes the importance of understanding the ancient and present-day knowledge of psychedelics to offer hope for individuals who have not responded to conventional treatment methods. [Extracted from the article]

A recent study conducted at the University of Freiburg examined the effects of psychedelic-assisted therapy (PAT) on patients with depression. The study compared the subjective effects of LSD and psilocybin between PAT patients and healthy volunteers. The results showed that PAT reduced depressive symptoms in the patient group, with the greatest predictor of antidepressant outcome being relaxation during the therapy session. The study also found that patients may experience more challenging psychedelic effects and reduced ego dissolution compared to healthy controls. The researchers suggest that further investigation into the impact of relaxation during PAT is needed. [Extracted from the article]

A recent study conducted by researchers at Rutgers University New Jersey Medical School explores the potential use of psychedelics as therapeutic agents for chronic pain. Chronic neuropathic pain affects a significant number of individuals worldwide, and traditional treatment options often come with adverse effects and suboptimal pain relief. The study suggests that psychedelics, such as psilocybin and lysergic acid diethylamide, may alter pain perception by activating serotonin receptors, exerting anti-inflammatory effects, and facilitating synaptic remodeling. This research provides insights into the mechanisms of action, pharmacology, clinical applications, and therapeutic potential of psychedelics in treating neuropathic pain. [Extracted from the article]

A recent report from Ohio State University highlights the urgent need for better treatments for mental health conditions that affect a significant portion of the global population. To address this concern, researchers have been studying the combination of psychedelic drugs and psychotherapy in clinical trials in the United States and Europe. While the results of trials using MDMA for trauma and psilocybin for depression show promise, there are still many unanswered questions about the safety and effectiveness of psychedelic-assisted therapy (PAT). The field of psychedelic research is currently at a crossroads, with the need to address obstacles and ethical concerns in order to transition from exploratory trials to evidence-based treatments. [Extracted from the article]

Researchers at the Institute of Salud Carlos III in Madrid, Spain have conducted a study on the comorbidity of schizophrenia and gambling disorder (GD). The aim of the study was to explore the symptoms and clinical correlates of schizophrenia with GD. Network analysis was applied to a sample of 179 schizophrenia patients with gambling disorder-related problems, and the variables with the highest relevance were found to be personality traits and psychological distress. The identification of these variables can be useful for developing precise management plans for the treatment of schizophrenia with GD. [Extracted from the article]

A recent study conducted at the University of Wisconsin explored the effects of co-administering the psychedelic psilocybin with the benzodiazepine midazolam. The researchers aimed to determine whether the therapeutic effects of psilocybin are immediate or based on memories of the experience. The study found that midazolam impaired memory while allowing for a conscious psychedelic experience. The researchers suggest that midazolam's ability to block memory could be useful in evaluating the therapeutic properties of psychedelics. This study provides insights into the potential role of memory in the therapeutic effects of psilocybin. [Extracted from the article]

A recent study conducted by researchers at Emory University, the University of Wisconsin-Madison, and UC Berkeley has estimated that between 56% and 62% of patients currently receiving treatment for depression in the United States could qualify for psilocybin-assisted therapy if it is approved by the FDA. This amounts to approximately 5.1 to 5.6 million individuals. The study analyzed national survey data on depression prevalence and treatment, as well as eligibility criteria from recent clinical trials. However, the researchers caution that these projections are contingent on FDA approval parameters and real-world implementation factors. [Extracted from the article]

SetSet, a new platform, has been launched to provide women with resources and support for safe microdosing of psychedelics. The platform aims to address the lack of education and support for women in the mental healthcare system and offers access to licensed therapists and medical providers, as well as a community for sharing experiences. SetSet hopes to onboard 10,000 founding members in the next year and is seeking $2 million in angel investment to expand its offerings. This launch comes at a time when women are turning to psychedelics as alternatives to traditional pharmaceutical treatments for anxiety and depression. [Extracted from the article]

Serotonergic psychedelics, such as LSD, psilocybin, and DMT, have shown promise as therapeutic agents for mood and anxiety disorders. The mechanism by which they exert their therapeutic effect is still debated, but one popular theory suggests that excessive 5-HT2a agonism disrupts cortical dynamics, making maladaptive beliefs more malleable and open to revision. A new energy-based model of cortical dynamics incorporating effects of neuromodulation proposes hypothetical computational mechanisms for both 5-HT2a and 5-HT1a agonism. The findings of this model suggest that biased 5-HT1a agonist psychedelics, like 5-MeO-DMT, could be fruitful in the development of more effective and tolerable psychotherapeutic agents in the future. [Extracted from the article]

A recent report from the University of Essex discusses the potential use of psychedelic drugs in the treatment of common mental health conditions. These drugs, such as psilocybin and lysergic acid diethylamide (LSD), are being developed by nearly 100 companies worldwide. The report highlights the need for research on economic analyses to inform policymakers' decisions, as well as the impact of psychedelic-assisted therapy (PAT) on employees' wellbeing. Additionally, the report suggests exploring employees' experiences of stigma around mental health, psychedelics, and PAT. This research aims to improve global mental health and work participation. [Extracted from the article]

A recent study conducted by researchers from Georgetown University examined the factors associated with "deaths of despair" in the United States, which include mortality related to drugs, alcohol, and suicide. The study found that while psychological and economic distress were modestly associated with these deaths, structural factors such as employment status and social integration were more strongly linked. The researchers concluded that subjective distress may not be the primary cause of deaths of despair, and that structural factors play a more significant role. This research provides valuable insights into understanding and addressing the underlying causes of these deaths. [Extracted from the article]

The article outlines a University of Auckland study protocol for a phase 2b randomized controlled trial assessing the effects of lysergic acid diethylamide (LSD) microdosing on major depressive disorder (MDD). Topics include the trial's double-dummy, triple-blind, and active placebo-controlled design, as well as its methods for evaluating safety, efficacy, and treatment outcomes.

The article reviews the effectiveness of single-dose versus two-dose psilocybin in treating major depressive disorder (MDD). It finds both dosing strategies significantly reduce depressive symptoms, with two doses showing potentially more pronounced effects. It mentions the study that calls for standardized trials to clarify if these benefits are due to dosage alone or other factors.

The article investigates how peyote ceremonies influence personal transformation, focusing on changes such as reduced substance abuse and improved well-being. Topics include the psychological impact of peyote, alterations in mental and physical health, and the potential therapeutic applications of psychedelics.

The article reports that the National Institutes of Health has awarded a 2.4 million U.S. dollars grant to a cross-disciplinary team from the Medical College of Wisconsin, UC San Diego, and LSU Health Shreveport to study psychedelics for treating methamphetamine addiction. Topics include the potential role of psychedelics in addressing stimulant use disorder, the focus on serotonin 5-HT2A receptor signaling, and the goal of developing targeted therapies with manageable psychedelic effects.

The article explores the potential of psychedelic-assisted therapy as a revolutionary approach to addiction treatment, highlighting recent research suggesting that psychedelics like psilocybin and MDMA, used alongside conventional therapy, can yield rapid and lasting benefits for substance use disorders. Topics include the promising outcomes of clinical trials, the need for more research and funding, and the importance of integrating psychotherapy with psychedelic treatment.

A preprint abstract from the Psychology & Psychiatry Journal discusses a study on the effects of psilocybin, a hallucinogenic compound found in certain mushrooms. The study examined the acute experience and long-term effects of psilocybin in a small group of healthy individuals. The results showed that repeated administration of psilocybin induced positive and lasting effects, regardless of previous experience, sex, or the setting in which it was administered. The study suggests that psilocybin is psychologically safe and supports its use in clinical trials. However, it should be noted that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted by researchers at Universiti Malaya in Kuala Lumpur, Malaysia, has found that the prevalence of psychological distress (PD) among youth in Peninsular Malaysia is a growing concern. The study analyzed data from a cohort of 416 participants who underwent mental health assessments at ages 15 and 20. The prevalence of PD significantly increased from 15.9% at age 15 to 34.6% at age 20. Factors such as parental mental health problems, Indian and other ethnicities, lower maternal education attainment, and alcohol consumption were found to be significantly associated with PD in youth. The study highlights the need for increased access to mental health care and the improvement of surveillance and prevention programs to protect the psychosocial well-being of youth. [Extracted from the article]

A scoping review conducted by researchers in Hamilton, Canada, explores the available literature on the use of psilocybin for medical purposes. The study found that there has been a recent resurgence of interest in psychedelic drugs, which have been of interest in medicine since the 1950s. The review included 193 published studies and 80 ongoing studies, with the most common indication being depression. The researchers concluded that there is a need for high-quality randomized trials on psilocybin and to explore its potential use in other indications, such as chronic pain. [Extracted from the article]

A recent study conducted by researchers at the University of Victoria explored the use of psychedelics in athletes and their attitudes towards psilocybin-assisted therapy (PAT) for concussion recovery. The study found that psychedelics were the third most used substance among athletes, with 35.8% reporting use in the past year. The research also revealed that both athletes and staff members were willing to engage in or support PAT for concussion recovery. However, further research is needed to examine the effects of psilocybin on post-concussion symptoms and address concerns about long-term effects. [Extracted from the article]

A clinical trial, NCT06512220, is currently underway to study the effects of psilocybin, the active compound in "magic mushrooms", on treatment-resistant depression (TRD). The trial aims to determine if psilocybin's antidepressant effects are linked to changes in synaptic density in adults with TRD. The study will administer psilocybin with or without risperidone and measure outcomes such as the feasibility of obtaining PET imaging scans and changes in synaptic density. The trial is expected to be completed by August 31, 2026. Additionally, another clinical trial is being planned to investigate the effects of combining psilocybin and risperidone in adults with non-psychotic major depressive disorder (MDD) who have not responded to previous antidepressant treatments. This trial will enroll 12 participants and is expected to be completed by August 2026. The eligibility criteria include being between 18 and 65 years old, having a diagnosis of non-psychotic MDD, and being willing to taper off current antidepressant and antipsychotic medications. The trial will take place in Canada. [Extracted from the article]

A study conducted by researchers at Murdoch University in Perth, Australia, analyzed data from online psychedelic forums to gain insights into psychedelic consumption. The study categorized and analyzed self-reported consumption of psychedelic substances, dosages, and administration routes to inform care services and guide clinical work with psychedelics. The study found that there was a correlation between greater psychedelic purity, dosage intensity, and a perceived need for care. The researchers concluded that more research is needed to understand factors influencing psychedelic care practices and that educational information should be provided to consumers to emphasize risk management strategies. [Extracted from the article]

A new report from researchers at the National University of Cordoba in Argentina explores the relationship between impulsivity, mental health, and alcohol and marijuana use. The study surveyed 1,507 Argentinean citizens about their alcohol and marijuana use, as well as their impulsivity traits, psychological distress, and emotion regulation strategies. The findings suggest that individuals with higher levels of impulsivity, depression symptoms, or lower use of emotional regulation abilities may be at a higher risk for alcohol or marijuana use. The study concludes that interventions aimed at enhancing emotion regulation could benefit individuals with risk factors for drug misuse. [Extracted from the article]

A recent study conducted by researchers at Washington University School of Medicine in St. Louis has found that psilocybin, the active compound in magic mushrooms, disrupts a critical network of brain areas involved in introspective thinking. This disruption explains the mind-altering effects of the drug and lays the groundwork for the development of psilocybin-based therapies for mental illnesses such as depression and post-traumatic stress disorder. The study provides a roadmap for evaluating the effects of psychoactive drugs on brain function and may accelerate drug development efforts for psychiatric illnesses. However, it is important to note that psilocybin is not approved by the FDA for any medical use, and self-medication with the drug is not recommended. [Extracted from the article]

A study conducted in Brazil investigated the adverse event profile of psilocybin mushrooms and their potential for abuse and risk to public health. The study analyzed data from 2007 to 2022 and found that psilocybin mushrooms accounted for a very small percentage of adverse events, with no fatalities reported. The study suggests that psilocybin mushrooms have a low-risk profile, but acknowledges the possibility of underreporting. The researchers emphasize the need for evidence-based regulatory discussions to ensure safe access to psilocybin for clinical and ceremonial purposes. [Extracted from the article]

A study conducted by researchers at Johns Hopkins University School of Medicine found that a 41-year-old fully vaccinated female with Long-COVID syndrome experienced significant relief from her symptoms after self-medicating with psilocybin and MDMA. Long-COVID, which refers to symptoms that persist after the acute phase of COVID-19, currently lacks effective holistic treatment options. The researchers emphasize the need for further research to assess the safety and efficacy of this therapy. This information is available in a case report published in Clinical Case Reports. [Extracted from the article]

A recent report from the University of Montreal discusses the use of psilocybin, a compound found in certain mushrooms, as a potential treatment for difficult-to-treat depression. The report presents a case study of an adult patient with depression who received psilocybin-assisted psychotherapy in combination with two serotoninergic antidepressants. The patient experienced mild adverse effects, such as headaches, but overall, the combination of psilocybin and antidepressants appeared to be safe. The researchers suggest that future studies should explore the possibility of administering psilocybin concurrently with antidepressants to improve treatment acceptability and accessibility. [Extracted from the article]

A recent study conducted at Hedi Chaker Hospital in Tunisia examined the mental health and psychological distress among medical residents. The study found that residents are exposed to high levels of stress and psychological pressures, with factors such as workload, addictive habits, and fatigue contributing to psychological distress. The research highlights the need for comprehensive support systems within medical training programs to address these challenges. The study provides valuable insights into the mental health challenges faced by medical residents and emphasizes the importance of tailored interventions and support mechanisms. [Extracted from the article]

A recent study conducted by researchers at the University of Zaragoza in Spain explores the relationship between recreational drug use and suicidal behavior. The study examines the impact of various substances, including alcohol, cannabis, cocaine, methamphetamine, heroin, nicotine, ketamine, psilocybin, MDMA, and LSD, on suicidal behavior. The research suggests that most substances have a negative effect on suicidal behavior, with the exception of ketamine and psilocybin, which may have a protective effect. However, further research is needed to understand the relationship between MDMA, LSD, and suicide. [Extracted from the article]

A recent report from Huazhong University of Science and Technology in Wuhan, China explores the potential use of psilocybin, a psychoactive compound found in hallucinogenic mushrooms, for the treatment of Alzheimer's disease (AD). The researchers discuss the pharmacological effects of psilocybin and its potential mechanisms for positively impacting AD, such as increased neural plasticity, reduced inflammation, and improvements in cognitive functions. They also address the ethical and legal considerations surrounding the use of psilocybin for AD treatment. The study suggests that psilocybin may have therapeutic potential in the management of AD, but further research is needed. [Extracted from the article]

A recent study conducted by researchers at Sunnybrook Health Sciences Centre explores the potential of psilocybin, a compound found in certain mushrooms, as a treatment for major depressive disorder (MDD) and persistent depressive disorder (PDD). The study aims to investigate how psilocybin affects brain networks associated with depression and whether it can induce neuroplastic changes that have lasting effects. Fifty participants diagnosed with MDD or PDD will be randomly assigned to receive either psilocybin or a placebo, and neuroimaging assessments will be conducted to measure changes in brain activity and blood flow. The study hopes to provide insights into the antidepressant mechanisms of psilocybin and identify early predictors of treatment response. [Extracted from the article]